Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways

Author(s): Clara Lemos, Ulrike Sack, Felicitas Schmid, Manisha Juneja, Ulrike Stein

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 5 , 2013

Become EABM
Become Reviewer


Colorectal cancer is one of the most common cancers worldwide and one of the leading causes of cancer-related death in the Western world. Tumor progression towards metastasis affects a large number of patients with colorectal cancer and seriously affects their clinical outcome. Therefore, considerable effort has been made towards the development of therapeutic strategies that can decrease or prevent colorectal cancer metastasis. Standard treatment of metastatic colorectal cancer with chemotherapy has been improved in the last 10 years by the addition of new targeted agents. The currently used antibodies bevacizumab, cetuximab and panitumumab target the VEGF and EGFR signaling pathways, which are crucial for tumor progression and metastasis. These antibodies have shown relevant efficacy in both first- and second-line treatment of metastatic colorectal cancer. Additionally, other signaling pathways, including the Wnt and HGF/Met pathways, have a well-established role in colorectal cancer progression and metastasis and constitute, therefore, promising targets for new therapeutic approaches. Several new drugs targeting these pathways, including different antibodies and small-molecule tyrosine kinase inhibitors, are currently being developed and tested in clinical trials. In this review, we summarize the new developments in this field, focusing on the inhibitors that show more promising results for use in colorectal cancer patients.

Keywords: Colorectal cancer, HGF/Met pathway, metastasis, molecular therapeutics, Wnt/β-catenin pathway, tumor, chemotherapy, bevacizumab, cetuximab, panitumumab

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [841 - 863]
Pages: 23
DOI: 10.2174/1381612811306050841
Price: $65

Article Metrics

PDF: 63